文献速递核素与放射性配体治疗肿瘤 PET/CT

MHC-I驱动的抗肿瘤免疫可抵消放射性药物治疗的低吸收剂量

MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.
PubMed 文献 · J Nucl Med · 2025-05-01

研究比较低与高表达MHC-I的黑色素瘤细胞系在免疫健全与免疫缺陷小鼠中对[225Ac]Ac-DOTA-TA99单次注射的反应,并分析甲状腺癌与中肠神经内分泌肿瘤患者样本的MHC-I表达。结果显示T细胞存在与MHC-I表达增强RPT疗效,低吸收剂量下MHC-I高表达肿瘤与4倍吸收剂量下MHC-I低表达肿瘤的照射反应相同,提示CD8+ T细胞可抵消低肿瘤照射。

要点

  • 在C57BL/6J免疫健全小鼠中RPT抗肿瘤效果强于无胸腺与裸免疫缺陷小鼠。
  • B16K1 MHC-I高表达肿瘤低吸收剂量α-RPT与B16F10 MHC-I低表达肿瘤4倍吸收剂量反应相同。
  • 高吸收剂量似乎阻止免疫系统激活,MHC-I可作为低吸收剂量病灶RPT反应的预测生物标志物。

核心结论

  • 本研究表明MHC-I表达可预测RPT的免疫刺激效应,这在同一患者不同病灶可接受极低或极高吸收剂量的转移性疾病中具有相关性。

研究设计与样本

  • 将表达低与高MHC-I水平的小鼠黑色素瘤细胞系B16F10与B16K1分别移植到同系或无胸腺与裸小鼠,评估单次注射[225Ac]Ac-DOTA-TA99单克隆抗体(9.25或18.5 kBq)的反应并与剂量学关联。
  • 在临床相关性方面,检测了分化良好、碘亲和性转移性甲状腺癌与分化良好2级中肠神经内分泌肿瘤患者样本中的MHC-I表达。

主要发现

  • RPT疗效被T细胞存在与MHC-I表达增强。
  • 在携带B16F10与B16K1黑色素瘤肿瘤的小鼠中,RPT在C57BL/6J免疫健全动物中比在无胸腺与裸免疫缺陷动物中显示更强的抗肿瘤效果,提示T细胞介导免疫反应的关键作用。
  • B16K1 MHC-I高表达肿瘤低吸收剂量α-RPT与B16F10 MHC-I低表达肿瘤4倍更高吸收剂量的照射反应相同,表明CD8+ T细胞可抵消低肿瘤照射。
  • 相反,递送高吸收剂量导致副作用并似乎阻止免疫系统激活,从而未利用这些机制。
  • 结果表明MHC-I可作为接受低吸收剂量病灶RPT反应的预测生物标志物,且RPT治疗方案应根据MHC-I表达水平重新考虑。

临床怎么用

  • 作者认为MHC-I表达可预测RPT免疫刺激效应,在转移性疾病中同一患者病灶可接受极低或极高吸收剂量时具有相关性。
  • 作者认为RPT治疗方案应根据MHC-I表达水平重新考虑。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy. Here, we investigated the role of major histocompatibility complex class I (MHC-I) molecules recognized by cytotoxic CD8+ T cells in the response to radiopharmaceutical therapy (RPT). Methods: Two murine melanoma cell lines that express low and high MHC-I levels (B16F10 and B16K1, respectively) were grafted in syngeneic or athymic and nude mice, and the response to a single injection of [225Ac]Ac-DOTA-TA99 monoclonal antibodies (9.25 or 18.5 kBq) was assessed and related to dosimetry. For clinical relevance, MHC-I expression was determined in samples from patients with well-differentiated, iodine-avid metastatic thyroid cancer and well-differentiated grade 2 mid-gut neuroendocrine tumors. Results: RPT efficacy was enhanced by T-cell presence and MHC-I expression. In mice harboring B16F10 and B16K1 melanoma tumors, RPT showed a stronger antitumor effect in C57BL/6J (immunocompetent) animals than in athymic and nude (immunodeficient) animals, suggesting a crucial role of T-cell-mediated immune responses. Moreover, the response to irradiation was the same in B16K1 MHC-Ihigh tumors with a low absorbed dose of α-RPT and in B16F10 MHC-Ilow tumors with a 4 times higher absorbed dose. These results indicate that CD8+ T cells can counterbalance low tumor irradiation. Conversely, delivering high absorbed doses leads to side effects and seems to prevent immune system activation, thereby not taking advantage of these mechanisms. Our results also indicate that MHC-I can be used as a predictive biomarker of RPT response in lesions receiving low absorbed doses and that RPT treatment regimens should be reconsidered in the function of the MHC-I expression level. Conclusion: This study shows that MHC-I expression can predict RPT immunostimulatory effects. This is relevant in metastatic disease where lesions in the same patient can receive very low or very high absorbed doses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Constanzo J, Parach A, David T, et al. MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 40015918. doi:10.2967/jnumed.124.268857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。